Overview of therapeutic drug research for COVID-19 in China

被引：0
作者：
Heng Li
Li Yang
Fei-fei Liu
Xin-na Ma
Pei-lan He
Wei Tang
Xian-kun Tong
Jian-ping Zuo
机构：
[1] Laboratory of Immunopharmacology,Laboratory of Immunology and Virology
[2] Shanghai Institute of MateriaMedica,undefined
[3] Chinese Academy of Sciences,undefined
[4] University of Chinese Academy of Sciences,undefined
[5] Shanghai University of Traditional Chinese Medicine,undefined
来源：
Acta Pharmacologica Sinica | 2020年 / 41卷
关键词：
SARS-CoV-2; COVID-19; novel coronavirus pneumonia; therapeutic drugs; anti-SARS-CoV-2 agents; favipiravir; hydroxychloroquine; traditional Chinese medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS-CoV-2 agents are also reviewed.
引用
收藏
页码：1133 / 1140
页数：7
相关论文
共 317 条
[1]  
Xu X(2020)Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission Sci China Life Sci 63 457-60
[2]  
Chen P(2020)Recent advances in the detection of respiratory virus infection in humans J Med Virol 92 408-17
[3]  
Wang J(2020)Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Emerg Microbes Infect. 9 221-36
[4]  
Feng J(2011)Coronavirus pathogenesis Adv Virus Res 81 85-164
[5]  
Zhou H(2015)Coronaviruses: an overview of their replication and pathogenesis Methods Mol Biol 1282 1-23
[6]  
Li X(2018)MERS, SARS and other coronaviruses as causes of pneumonia Respirology 23 130-7
[7]  
Zhang N(2009)Coronaviruses post-SARS: update on replication and pathogenesis Nat Rev Microbiol 7 439-50
[8]  
Wang L(2018)Host factors in coronavirus replication Curr Top Microbiol Immunol 419 1-42
[9]  
Deng X(2016)SARS and MERS: recent insights into emerging coronaviruses Nat Rev Microbiol 14 523-34
[10]  
Liang R(2020)A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Lancet 395 514-23
12345678910